Therapeutic options in peripheral T cell lymphoma

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

(2016) Francine Foss et al.   Journal of Hematology & Oncology

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

(2015) Byeong-Bae Park et al.   ANNALS OF HEMATOLOGY

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease

(2015) Amer Beitinjaneh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

(2015) T. E. Witzig et al.   BLOOD

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

(2015) C. Wang et al.   BLOOD

Development and validation of a sensitive HPLC–MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application

(2015) Ruolan Gu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

(2015) Paul M. Barr et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

(2015) Jehan Dupuis et al.   Lancet Haematology

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)

(2014) R. Dummer et al.   ANNALS OF ONCOLOGY

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Efficacy of 5-Azacytidine in aTET2mutated angioimmunoblastic T cell lymphoma

(2014) Morgane Cheminant et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma

(2014) Juliet Fraser Gibson et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

(2014) Francine Foss et al.   BRITISH JOURNAL OF HAEMATOLOGY

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

(2014) Ethan Toumishey et al.   CANCER

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study

(2014) Michelle A. Fanale et al.   JOURNAL OF CLINICAL ONCOLOGY

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

(2014) Bertrand Coiffier et al.   Journal of Hematology & Oncology

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

(2014) Carlo Gambacorti Passerini et al.   JNCI-Journal of the National Cancer Institute

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

(2014) S E Assouline et al.   Blood Cancer Journal

CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial

(2013) C. Binder et al.   ANNALS OF HEMATOLOGY

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

(2013) Andrew M. Evens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies

(2013) Madeleine Duvic et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

(2013) Franck Morschhauser et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential expression of aurora-A kinase in T-cell lymphomas

(2013) Rashmi Kanagal-Shamanna et al.   MODERN PATHOLOGY

The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies

(2013) Lionel Karlin et al.   SEMINARS IN HEMATOLOGY

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

(2012) Seok Jin Kim et al.   EUROPEAN JOURNAL OF CANCER

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

(2012) Madeleine Duvic et al.   EUROPEAN JOURNAL OF CANCER

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

(2012) Takashi Ishida et al.   JOURNAL OF CLINICAL ONCOLOGY

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

(2012) Francesco d'Amore et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

(2011) Peter J. Hosein et al.   AMERICAN JOURNAL OF HEMATOLOGY

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

(2011) T. E. Witzig et al.   BLOOD

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2010) N. Schmitz et al.   BLOOD

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

(2010) Francesco D’Amore et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

(2010) Greg Dueck et al.   CANCER

L-Asparaginase-Induced Complete Response in a Relapsed Patient with Epstein-Barr Virus and Cytotoxic Peripheral T-Cell Lymphoma Not Otherwise Specified

(2010) Tsutomu Takahashi et al.   INTERNAL MEDICINE

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

(2010) Eckhart Weidmann et al.   LEUKEMIA & LYMPHOMA

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

(2009) P. L. Zinzani et al.   ANNALS OF ONCOLOGY

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

(2009) Lena Marquard et al.   HISTOPATHOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY